Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66047, United States.
SUMO Biosciences, Inc., 2265 East Foothill Boulevard, Pasadena, California 91107, United States.
J Phys Chem Lett. 2023 Mar 23;14(11):2792-2799. doi: 10.1021/acs.jpclett.3c00253. Epub 2023 Mar 10.
Post-translational modifications by small ubiquitin-like modifiers (SUMOs) are dysregulated in many types of cancers. The SUMO E1 enzyme has recently been suggested as a new immuno-oncology target. COH000 was recently identified as a highly specific allosteric covalent inhibitor of SUMO E1. However, a marked discrepancy was found between the X-ray structure of the covalent COH000-bound SUMO E1 complex and the available structure-activity relationship (SAR) data of inhibitor analogues due to unresolved noncovalent protein-ligand interactions. Here, we have investigated noncovalent interactions between COH000 and SUMO E1 during inhibitor dissociation through novel Ligand Gaussian accelerated molecular dynamics (LiGaMD) simulations. Our simulations have identified a critical low-energy non-covalent binding intermediate conformation of COH000 that agreed excellently with published and new SAR data of the COH000 analogues, which were otherwise inconsistent with the X-ray structure. Altogether, our biochemical experiments and LiGaMD simulations have uncovered a critical non-covalent binding intermediate during allosteric inhibition of the SUMO E1 complex.
小泛素样修饰物(SUMO)介导的翻译后修饰在多种癌症中失调。SUMO E1酶最近被认为是一种新的免疫肿瘤学靶点。COH000最近被鉴定为SUMO E1的一种高度特异性变构共价抑制剂。然而,由于未解决的非共价蛋白质-配体相互作用,共价结合COH000的SUMO E1复合物的X射线结构与抑制剂类似物的现有构效关系(SAR)数据之间存在明显差异。在这里,我们通过新型配体高斯加速分子动力学(LiGaMD)模拟研究了抑制剂解离过程中COH000与SUMO E1之间的非共价相互作用。我们的模拟确定了COH000的一种关键低能非共价结合中间构象,该构象与COH000类似物已发表的和新的SAR数据高度吻合,否则这些数据与X射线结构不一致。总之,我们的生化实验和LiGaMD模拟揭示了SUMO E1复合物变构抑制过程中的一种关键非共价结合中间体。